Literature DB >> 2198809

Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene.

D D Koeberl1, C D Bottema, R P Ketterling, P J Bridge, D P Lillicrap, S S Sommer.   

Abstract

Spontaneous mutation provides the substrate for evolution on one hand and for genetic susceptibility to disease on the other hand. X-linked diseases such as hemophilia B offer an opportunity to examine recent germ-line mutations in humans. By utilizing the direct sequencing method of genomic amplification with transcript sequencing, eight regions (2.46 kb) of likely functional significance in the factor IX gene have been sequenced in a total of 60 consecutive, unrelated hemophiliacs. The high frequency of patient ascertainment from three regions in the midwestern United States and Canada suggests that the sample is representative of hemophiliacs of northern European descent. Twenty-six of the delineated mutations are reported herein, and the group of 60 is analyzed as a whole. From the pattern of mutations causing disease and from a knowledge of evolutionarily conserved amino acids, it is possible to reconstruct the underlying pattern of mutation and to calculate the mutation rates per base pair per generation for transitions (27 x 10(-10)), transversions (4.1 x 10(-10), and deletions (0.9 x 10(-10)) for a total mutation rate of 32 x 10(-10). The proportion of transitions at non-CpG nucleotides is elevated sevenfold over that expected if one base substitution were as likely as another. At the dinucleotide CpG, transitions are elevated 24-fold relative to transitions at other sites. The pattern of spontaneous mutations in factor IX resembles that observed in Escherichia coli when the data are corrected for ascertainment bias. The aggregate data hint that most mutations may be due to endogenous processes. The following additional conclusions emerge from the data: (1) Although in recent decades reproductive fitness in individuals with mild and moderate hemophilia has been approximately normal, the large number of different mutations found strongly suggest that these levels of disease substantially compromised reproduction in previous centuries. (2) Mutations which putatively affect splicing account for at least 13% of independent mutations, indicating that the division of the gene into eight exons presents a significant genetic cost for the organism. In one individual a "silent" mutation at lysine 5 is likely to cause hemophilia by generating a perfect splice donor consensus sequence in exon b. (3) All the missense mutations occurred at evolutionarily conserved amino acids. As additional data are generated on the pattern of mutations caused by specific mutagens, it will be possible to utilize the pattern of spontaneous mutation to estimate the maximal contribution of that mutagen during the past century.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2198809      PMCID: PMC1683712     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  66 in total

Review 1.  Dystrophin. The gene and its product.

Authors:  J L Mandel
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

2.  Recurrent mutations in haemophilia A give evidence for CpG mutation hotspots.

Authors:  H Youssoufian; H H Kazazian; D G Phillips; S Aronis; G Tsiftis; V A Brown; S E Antonarakis
Journal:  Nature       Date:  1986 Nov 27-Dec 3       Impact factor: 49.962

3.  Mechanisms of spontaneous mutagenesis: an analysis of the spectrum of spontaneous mutation in the Escherichia coli lacI gene.

Authors:  R M Schaaper; B N Danforth; B W Glickman
Journal:  J Mol Biol       Date:  1986-05-20       Impact factor: 5.469

4.  Mutations in the catalytic domain of human coagulation factor IX: rapid characterization by direct genomic sequencing of DNA fragments displaying an altered melting behavior.

Authors:  O Attree; D Vidaud; M Vidaud; S Amselem; J M Lavergne; M Goossens
Journal:  Genomics       Date:  1989-04       Impact factor: 5.736

5.  A Dutch family with moderately severe hemophilia B (factor IXHeerde) has a missense mutation identical to that of factor IX London 2.

Authors:  S R Poort; E Briët; R M Bertina; P H Reitsma
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

6.  Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.

Authors:  J Ware; D L Diuguid; H A Liebman; M J Rabiet; C K Kasper; B C Furie; B Furie; D W Stafford
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

7.  Blood clotting factor IX Niigata: substitution of alanine-390 by valine in the catalytic domain.

Authors:  M Sugimoto; T Miyata; S Kawabata; A Yoshioka; H Fukui; H Takahashi; S Iwanaga
Journal:  J Biochem       Date:  1988-12       Impact factor: 3.387

8.  Direct detection of point mutations by mismatch analysis: application to haemophilia B.

Authors:  A J Montandon; P M Green; F Giannelli; D R Bentley
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

9.  A new trisaccharide sugar chain linked to a serine residue in bovine blood coagulation factors VII and IX.

Authors:  S Hase; S Kawabata; H Nishimura; H Takeya; T Sueyoshi; T Miyata; S Iwanaga; T Takao; Y Shimonishi; T Ikenaka
Journal:  J Biochem       Date:  1988-12       Impact factor: 3.387

10.  Molecular pathology of haemophilia B.

Authors:  P M Green; D R Bentley; R S Mibashan; I M Nilsson; F Giannelli
Journal:  EMBO J       Date:  1989-04       Impact factor: 11.598

View more
  47 in total

1.  Screening for mutations by RNA single-strand conformation polymorphism (rSSCP): comparison with DNA-SSCP.

Authors:  G Sarkar; H S Yoon; S S Sommer
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

2.  Haemophilia B: database of point mutations and short additions and deletions--second edition.

Authors:  F Giannelli; P M Green; K A High; S Sommer; D P Lillicrap; M Ludwig; K Olek; P H Reitsma; M Goossens; A Yoshioka
Journal:  Nucleic Acids Res       Date:  1991-04-25       Impact factor: 16.971

3.  Haemophilia B: database of point mutations and short additions and deletions--third edition, 1992.

Authors:  F Giannelli; P M Green; K A High; S Sommer; D P Lillicrap; M Ludwig; K Olek; P H Reitsma; M Goossens; A Yoshioka
Journal:  Nucleic Acids Res       Date:  1992-05-11       Impact factor: 16.971

4.  Missense mutations and the magnitude of functional deficit: the example of factor IX.

Authors:  S S Sommer; E J Bowie; R P Ketterling; C D Bottema
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

Review 5.  Progress in the DNA diagnosis of hemophilias.

Authors:  M Goossens; N Ghanem
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

6.  High male:female ratio of germ-line mutations: an alternative explanation for postulated gestational lethality in males in X-linked dominant disorders.

Authors:  G H Thomas
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

7.  Understanding missense mutations in the BRCA1 gene: an evolutionary approach.

Authors:  Melissa A Fleming; John D Potter; Christina J Ramirez; Gary K Ostrander; Elaine A Ostrander
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-16       Impact factor: 11.205

8.  HhaI and HpaII DNA methyltransferases bind DNA mismatches, methylate uracil and block DNA repair.

Authors:  A S Yang; J C Shen; J M Zingg; S Mi; P A Jones
Journal:  Nucleic Acids Res       Date:  1995-04-25       Impact factor: 16.971

9.  HpaII methyltransferase is mutagenic in Escherichia coli.

Authors:  B Bandaru; M Wyszynski; A S Bhagwat
Journal:  J Bacteriol       Date:  1995-05       Impact factor: 3.490

10.  Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII.

Authors:  R Vervoort; M R Islam; W S Sly; M T Zabot; W J Kleijer; A Chabas; A Fensom; E P Young; I Liebaers; W Lissens
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.